RIP kinases and necroptosis in aging and aging-related diseases

Abstract

Aging is a natural process that is characterized by chronic, low-grade inflammation, which represents the primary risk factor in the pathogenesis of a variety of diseases, i.e. aging-related diseases. RIP kinases, in particular RIPK1 and RIPK3, have emerged as master regulators of proinflammatory responses that act either by causing apoptosis and necroptosis or by directly regulating intracellular inflammatory signaling. While, RIPK1/3 and necroptosis are intimately linked to multiple human diseases, the relationship among RIPK1/3, necroptosis, and aging remains unclear. In this review, we discuss current evidence arguing for the involvement of RIPK1/3 and necroptosis in the progression of aging. In addition, we provide updated information and knowledge on the role of RIPK1/3 and necroptosis in aging-related diseases. Leveraging these new mechanistic insights in aging, we postulate how our improved understanding of RIPK1/3 and necroptosis in aging may support the development of therapeutics targeting RIPK1/3 and necroptosis for the modulation of aging and treatment of aging-related diseases.

Keywords

RIPK1 / RIPK3 / necroptosis / aging / inflammation

References

[1] Partridge L, Deelen J, Slagboom PE. Facing up to the global challenges of ageing. Nature 2018;561:45–56.

[2] Campisi J, Kapahi P, Lithgow GJ, et al. From discoveries in ageing research to therapeutics for healthy ageing. Nature 2019;571:183–92.

[3] Kennedy BK, Berger SL, Brunet A, et al. Geroscience: linking aging to chronic disease. Cell 2014;159:709–13.

[4] Ferrucci L, Corsi A, Lauretani F, et al. The origins of age-related proinflammatory state. Blood 2005;105:2294–9.

[5] Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 2013;493:674–8.

[6] Youm YH, Adijiang A, Vandanmagsar B, et al. Elimination of the NLRP3-ASC inflammasome protects against chronic obesity-induced pancreatic damage. Endocrinology 2011;152:4039–45.

[7] Xu D, Zou C, Yuan J. Genetic regulation of RIPK1 and necroptosis. Annu Rev Genet 2021;55:235–63.

[8] Stanger BZ, Leder P, Lee TH, et al. RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995;81:513–23.

[9] Degterev A, Hitomi J, Germscheid M, et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol 2008;4:313–21.

[10] Sun X, Lee J, Navas T, et al. RIP3, a novel apoptosis-inducing kinase. J Biol Chem 1999;274:16871–5.

[11] Sun X, Yin J, Starovasnik MA, et al. Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J Biol Chem 2002;277:9505–11.

[12] Li J, McQuade T, Siemer AB, et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 2012;150:339–50.

[13] Mifflin L, Ofengeim D, Yuan J. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov 2020;19:553–71.

[14] He S, Wang X. RIP kinases as modulators of inflammation and immunity. Nat Immunol 2018;19:912–22.

[15] Dondelinger Y, Declercq W, Montessuit S, et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep 2014;7:971–81.

[16] Wang H, Sun L, Su L, et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Mol Cell 2014;54:133–46.

[17] Choi ME, Price DR, Ryter SW, et al. Necroptosis: a crucial pathogenic mediator of human disease. JCI Insight 2019;4.

[18] Shan B, Pan H, Najafov A, et al. Necroptosis in development and diseases. Genes Dev 2018;32:327–40.

[19] Christofferson DE, Li Y, Yuan J. Control of life-or-death decisions by RIP1 kinase. Annu Rev Physiol 2014;76:129–50.

[20] Ting AT, Bertrand MJM. More to life than NF-kappaB in TNFR1 signaling. Trends Immunol 2016;37:535–45.

[21] Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003;114:181–90.

[22] Hsu H, Shu HB, Pan MG, et al. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 1996;84:299–308.

[23] Bertrand MJ, Milutinovic S, Dickson KM, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008;30:689–700.

[24] Ikeda F, Deribe YL, Skanland SS, et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. Nature 2011;471:637–41.

[25] Gerlach B, Cordier SM, Schmukle AC, et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature 2011;471:591–6.

[26] Tokunaga F, Nakagawa T, Nakahara M, et al. SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. Nature 2011;471:633–6.

[27] Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012;26:203–34.

[28] Micheau O, Lens S, Gaide O, et al. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol 2001;21:5299–305.

[29] Chang DW, Xing Z, Pan Y, et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002;21:3704–14.

[30] Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 2008;133:693–703.

[31] Dillon CP, Weinlich R, Rodriguez DA, et al. RIPK1 blocks early postnatal lethality mediated by caspase-8 and RIPK3. Cell 2014;157:1189–202.

[32] Cuchet-Lourenco D, Eletto D, Wu C, et al. Biallelic RIPK1 mutations in humans cause severe immunodeficiency, arthritis, and intestinal inflammation. Science 2018;361:810–3.

[33] Li Y, Fuhrer M, Bahrami E, et al. Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases. Proc Natl Acad Sci U S A 2019;116:970–5.

[34] Uchiyama Y, Kim CA, Pastorino AC, et al. Primary immunodeficiency with chronic enteropathy and developmental delay in a boy arising from a novel homozygous RIPK1 variant. J Hum Genet 2019;64:955–60.

[35] Newton K, Wickliffe KE, Maltzman A, et al. RIPK1 inhibits ZBP1-driven necroptosis during development. Nature 2016;540:129–33.

[36] Takaoka A, Wang Z, Choi MK, et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007;448:501–5.

[37] Gay NJ, Symmons MF, Gangloff M, et al. Assembly and localization of Toll-like receptor signalling complexes. Nat Rev Immunol 2014;14:546–58.

[38] Polykratis A, Hermance N, Zelic M, et al. Cutting edge: RIPK1 kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo. J Immunol 2014;193:1539–43.

[39] Berger SB, Kasparcova V, Hoffman S, et al. Cutting edge: RIP1 kinase activity is dispensable for normal development but is a key regulator of inflammation in SHARPIN-deficient mice. J Immunol 2014;192:5476–80.

[40] Kaiser WJ, Daley-Bauer LP, Thapa RJ, et al. RIP1 suppresses innate immune necrotic as well as apoptotic cell death during mammalian parturition. Proc Natl Acad Sci U S A 2014;111:7753–8.

[41] Ofengeim D, Ito Y, Najafov A, et al. Activation of necroptosis in multiple sclerosis. Cell Rep 2015;10:1836–49.

[42] Laurien L, Nagata M, Schunke H, et al. Autophosphorylation at serine 166 regulates RIP kinase 1-mediated cell death and inflammation. Nat Commun 2020;11:1747.

[43] Huang X, Tan S, Li Y, et al. Caspase inhibition prolongs inflammation by promoting a signaling complex with activated RIPK1. J Cell Biol 2021;220:e202007127.

[44] Li W, Shan B, Zou C, et al. Nuclear RIPK1 promotes chromatin remodeling to mediate inflammatory response. Cell Res 2022:1–17.

[45] Geng J, Ito Y, Shi L, et al. Regulation of RIPK1 activation by TAK1-mediated phosphorylation dictates apoptosis and necroptosis. Nat Commun 2017;8:359.

[46] Dondelinger Y, Jouan-Lanhouet S, Divert T, et al. NF-kappaB-independent role of IKKalpha/IKKbeta in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during TNF signaling. Mol Cell 2015;60:63–76.

[47] Wertz IE, O’Rourke KM, Zhou H, et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004;430:694–9.

[48] Xu D, Jin T, Zhu H, et al. TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging. Cell 2018;174:1477–91.

[49] Newton K, Wickliffe KE, Maltzman A, et al. Activity of caspase-8 determines plasticity between cell death pathways. Nature 2019;575:679–82.

[50] Lin Y, Devin A, Rodriguez Y, et al. Cleavage of the death domain kinase RIP by caspase-8 prompts TNF-induced apoptosis. Genes Dev 1999;13:2514–26.

[51] Zhu K, Liang W, Ma Z, et al. Necroptosis promotes cell-autonomous activation of proinflammatory cytokine gene expression. Cell Death Dis 2018;9:500.

[52] Kaiser WJ, Offermann MK. Apoptosis induced by the toll-like receptor adaptor TRIF is dependent on its receptor interacting protein homotypic interaction motif. J Immunol 2005;174:4942–52.

[53] Kaiser WJ, Upton JW, Mocarski ES. Receptor-interacting protein homotypic interaction motif-dependent control of NF-kappa B activation via the DNA-dependent activator of IFN regulatory factors. J Immunol 2008;181:6427.

[54] Kaiser WJ, Upton JW, Mocarski ES, et al. Toll-like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem 2013;288: 31268–79.

[55] He S, Liang Y, Shao F, et al. Toll-like receptors activate programmed necrosis in macrophages through a receptor-interacting kinase-3-mediated pathway. Proc Natl Acad Sci U S A 2011;108:20054–9.

[56] Zhang DW, Shao J, Lin J, et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009;325:332–6.

[57] He S, Wang L, Miao L, et al. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009;137:1100–11.

[58] Cho YS, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell 2009;137:1112–23.

[59] Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012;148:213–27.

[60] Garnish SE, Meng Y, Koide A, et al. Conformational interconversion of MLKL and disengagement from RIPK3 precede cell death by necroptosis. Nat Commun 2021;12:2211.

[61] Petrie EJ, Sandow JJ, Jacobsen AV, et al. Conformational switching of the pseudokinase domain promotes human MLKL tetramerization and cell death by necroptosis. Nat Commun 2018;9:2422.

[62] Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001;1:135–45.

[63] Upton JW, Kaiser WJ, Mocarski ES. DAI/ZBP1/DLM-1 complexes with RIP3 to mediate virus-induced programmed necrosis that is targeted by murine cytomegalovirus vIRA. Cell Host Microbe 2012;11:290–7.

[64] Zhang T, Yin C, Boyd DF, et al. Influenza virus Z-RNAs induce ZBP1-mediated necroptosis. Cell 2020;180:1115–29.

[65] Jiao H, Wachsmuth L, Kumari S, et al. Z-nucleic-acid sensing triggers ZBP1-dependent necroptosis and inflammation. Nature 2020;580:391–5.

[66] Wang R, Li H, Wu J, et al. Gut stem cell necroptosis by genome instability triggers bowel inflammation. Nature 2020;580:386–90.

[67] Belshaw R, Pereira V, Katzourakis A, et al. Long-term reinfection of the human genome by endogenous retroviruses. Proc Natl Acad Sci U S A 2004;101:4894–9.

[68] Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J GerontolA: Biol SciMed Sci 2014;69:S4–9.

[69] Goldberg EL, Dixit VD. Drivers of age-related inflammation and strategies for healthspan extension. Immunol Rev 2015;265:63–74.

[70] Gong T, Liu L, Jiang W, et al. DAMP-sensing receptors in sterile inflammation and inflammatory diseases. Nat Rev Immunol 2020;20:95–112.

[71] Royce GH, Brown-Borg HM, Deepa SS. The potential role of necroptosis in inflammaging and aging. Geroscience 2019;41:795–811.

[72] Hanauer SB. Obesity and visceral fat: a growing inflammatory disease. Nat Clin Pract Gastroenterolo Hepatol 2005;2:245.

[73] Alvehus M, Buren J, Sjostrom M, et al. The human visceral fat depot has a unique inflammatory profile. Obesity (Silver Spring) 2010;18:879–83.

[74] Deepa SS, Unnikrishnan A, Matyi S, et al. Necroptosis increases with age and is reduced by dietary restriction. Aging Cell 2018;17.

[75] Spaulding CC, Walford RL, Effros RB. Calorie restriction inhibits the age-related dysregulation of the cytokines TNF-α and IL-6 in C3B10RF1 mice. Mech Ageing Dev 1997;93:87–94.

[76] Pizza V, Agresta A, D’Acunto CW, et al. Neuroinflamm-aging and neurodegenerative diseases: an overview. CNS Neurol Disord Drug Targets 2011;10:621–34.

[77] Cunningham C. Microglia and neurodegeneration: the role of systemic inflammation. Glia 2013;61:71–90.

[78] Okun E, Griffioen KJ, Lathia JD, et al. Toll-like receptors in neurodegeneration. Brain Res Rev 2009;59:278–92.

[79] Thadathil N, Nicklas EH, Mohammed S, et al. Necroptosis increases with age in the brain and contributes to age-related neuroinflammation. Geroscience 2021;43:2345–61.

[80] Arrázola MS, Lira M, Quiroz G, et al. Necroptosis inhibition counteracts axonal degeneration, cognitive decline and key hallmarks of aging, promoting brain rejuvenation. bioRxiv 2022.

[81] Mohammed S, Thadathil N, Selvarani R, et al. Necroptosis contributes to chronic inflammation and fibrosis in aging liver. Aging Cell 2021;20:e13512.

[82] Sun YY, Li XF, Meng XM, et al. Macrophage phenotype in liver injury and repair. Scand J Immunol 2017;85:166–74.

[83] Mohammed S, Nicklas EH, Thadathil N, et al. Role of necroptosis in chronic hepatic inflammation and fibrosis in a mouse model of increased oxidative stress. Free Radic Biol Med 2021;164:315–28.

[84] Li D, Meng L, Xu T, et al. RIPK1-RIPK3-MLKL-dependent necrosis promotes the aging of mouse male reproductive system. eLife 2017;6.

[85] Finch CE, Girgis FG. Enlarged seminal vesicles of senescent C57BL-6J mice. J Gerontol 1974;29:134–8.

[86] Bowl MR, Dawson SJ. Age-related hearing loss. Cold Spring Harb Perspect Med 2019;9.

[87] Moreno-Gonzalez G, Vandenabeele P, Krysko DV. Necroptosis: a novel cell death modality and its potential relevance for critical care medicine. Am J Respir Crit Care Med 2016;194:415–28.

[88] Lyu AR, Kim TH, Park SJ, et al. Mitochondrial damage and necroptosis in aging cochlea. Int J Mol Sci 2020;21.

[89] Ballard C, Gauthier S, Corbett A, et al. Alzheimer’s disease. Lancet 2011;377:1019–31.

[90] Caccamo A, Branca C, Piras IS, et al. Necroptosis activation in Alzheimer’s disease. Nat Neurosci 2017;20:1236–46.

[91] Koper MJ, Van Schoor E, Ospitalieri S, et al. Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer’s disease. Acta Neuropathol 2020;139:463–84.

[92] Salvadores N, Moreno-Gonzalez I, Gamez N, et al. Abeta oligomers trigger necroptosis-mediated neurodegeneration via microglia activation in Alzheimer’s disease. Acta Neuropathol Commun 2022;10:31.

[93] Ofengeim D, Mazzitelli S, Ito Y, et al. RIPK1 mediates a disease-associated microglial response in Alzheimer’s disease. Proc Natl Acad Sci U S A 2017;114:E8788–97.

[94] Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer’s disease. Cell 2017;169:1276–90.

[95] de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol 2006;5:525–35.

[96] Iannielli A, Bido S, Folladori L, et al. Pharmacological inhibition of necroptosis protects from dopaminergic neuronal cell death in Parkinson’s disease models. Cell Rep 2008;22:2066–79.

[97] Lin QS, Chen P, Wang WX, et al. RIP1/RIP3/MLKL mediates dopaminergic neuron necroptosis in a mouse model of Parkinson disease. Lab Invest 2020;100:503–11.

[98] Onate M, Catenaccio A, Salvadores N, et al. The necroptosis machinery mediates axonal degeneration in a model of Parkinson disease. Cell Death Differ 2020;27:1169–85.

[99] Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol 2017;13:96–104.

[100] Conforti L, Gilley J, Coleman MP. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat Rev Neurosci 2014;15:394–409.

[101] Re DB, Le Verche V, Yu C, et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron 2014;81:1001–8.

[102] Ito Y, Ofengeim D, Najafov A, et al. RIPK1 mediates axonal degeneration by promoting inflammation and necroptosis in ALS. Science 2016;353:603–8.

[103] Freischmidt A, Wieland T, Richter B, et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nature Neurosci 2015;18, 631–6.

[104] Koo GB, Morgan MJ, Lee DG, et al. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. Cell Res 2015;25:707–25.

[105] Moriwaki K, Bertin J, Gough PJ, et al. Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death. Cell Death Dis 2015;6:e1636.

[106] Feng X, Song Q, Yu A, et al. Receptor-interacting protein kinase 3 is a predictor of survival and plays a tumor suppressive role in colorectal cancer. Neoplasma 2015;62:592–601.

[107] Nugues AL, El Bouazzati H, Hetuin D, et al. RIP3 is downregulated in human myeloid leukemia cells and modulates apoptosis and caspase-mediated p65/RelA cleavage. Cell Death Dis 2014;5:e1384.

[108] Park JE, Lee JH, Lee SY, et al. Expression of key regulatory genes in necroptosis and its effect on the prognosis in non-small cell lung cancer. J Cancer 2020;11:5503–10.

[109] Yang C, Li J, Yu L, et al. Regulation of RIP3 by the transcription factor Sp1 and the epigenetic regulator UHRF1 modulates cancer cell necroptosis. Cell Death Dis 2017;8:e3084.

[110] Najafov A, Zervantonakis IK, Mookhtiar AK, et al. BRAF and AXL oncogenes drive RIPK3 expression loss in cancer. PLoS Biol 2018;16:e2005756.

[111] Park S, Hatanpaa KJ, Xie Y, et al. The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res 2009;69:2809–16.

[112] Wang Q, Chen W, Xu X, et al. RIP1 potentiates BPDE-induced transformation in human bronchial epithelial cells through catalase-mediated suppression of excessive reactive oxygen species. Carcinogenesis 2013;34:2119–29.

[113] Liu XY, Lai F, Yan XG, et al. RIP1 kinase is an oncogenic driver in melanoma. Cancer Res 2015;75:1736–48.

[114] Wang C, Yao B, Xu M, et al. RIP1 upregulation promoted tumor progression by activating AKT/Bcl-2/BAX signaling and predicted poor postsurgical prognosis in HCC. Tumour Biol 2016;37:15305–13.

[115] Liu ZY, Wu B, Guo YS, et al. Necrostatin-1 reduces intestinal inflammation and colitis-associated tumorigenesis in mice. Am J Cancer Res 2015;5:3174–85.

[116] Wang W, Marinis JM, Beal AM, et al. RIP1 kinase drives macrophage-mediated adaptive immune tolerance in pancreatic cancer. Cancer Cell 2018;34:757–74.e7.

[117] Yatim N, Jusforgues-Saklani H, Orozco S, et al. RIPK1 and NF-kappaB signaling in dying cells determines cross-priming of CD8(+) T cells. Science 2015;350:328–34.

[118] Aaes TL, Kaczmarek A, Delvaeye T, et al. Vaccination with necroptotic cancer cells induces efficient anti-tumor immunity. Cell Rep 2016;15:274–87.

[119] Snyder AG, Hubbard NW, Messmer MN, et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci Immunol 2019;4.

[120] Seifert L, Werba G, Tiwari S, et al. The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression. Nature 2016;532:245–9.

[121] Ando Y, Ohuchida K, Otsubo Y, et al. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. PLoS One 2020;15:e0228015.

[122] Xin J, You D, Breslin P, et al. Sensitizing acute myeloid leukemia cells to induced differentiation by inhibiting the RIP1/RIP3 pathway. Leukemia 2017;31:1154–65.

[123] Strilic B, Yang L, Albarran-Juarez J, et al. Tumour-cell-induced endothelial cell necroptosis via death receptor 6 promotes metastasis. Nature 2016;536:215–18.

[124] Gabr A, Kini SG, Haddad FS. Osteoarthritis. In: Paschos N, Bentley G (eds.), General Orthopaedics and Basic Science. Orthopaedic Study Guide Series. Springer, Cham, Chapter 15. 2019, 121–31.

[125] Hosseinzadeh A, Kamrava SK, Joghataei MT, et al. Apoptosis signaling pathways in osteoarthritis and possible protective role of melatonin. J Pineal Res 2016;61:411–25.

[126] Liang S, Lv ZT, Zhang JM, et al. Necrostatin-1 attenuates trauma-induced mouse osteoarthritis and IL-1beta induced apoptosis via HMGB1/TLR4/SDF-1 in primary mouse chondrocytes. Front Pharmacol 2018;9:1378.

[127] Cheng J, Duan X, Fu X, et al. RIP1 perturbation induces chondrocyte necroptosis and promotes osteoarthritis pathogenesis via targeting BMP7. Front Cell Dev Biol 2021;9:638382.

[128] Riegger J, Brenner RE. Evidence of necroptosis in osteoarthritic disease: investigation of blunt mechanical impact as possible trigger in regulated necrosis. Cell Death Dis 2019;10:683.

[129] Stolberg-Stolberg J, Sambale M, Hansen U, et al. Cartilage trauma induces necroptotic chondrocyte death and expulsion of cellular contents. Int J Mol Sci 2020;21.

[130] Lakatta EG. Age-associated cardiovascular changes in health: impact on cardiovascular disease in older persons. Heart Fail Rev 2002;7:29–49.

[131] Smith CC, Davidson SM, Lim SY, et al. Necrostatin: a potentially novel cardioprotective agent? Cardiovasc Drugs Ther 2007;21:227–33.

[132] Oerlemans MI, Liu J, Arslan F, et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia- reperfusion in vivo. Basic Res Cardiol 2012;107:270.

[133] Luedde M, Lutz M, Carter N, et al. RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. Cardiovasc Res 2014;103:206–16.

[134] Zhang T, Zhang Y, Cui M, et al. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress–induced myocardial necroptosis. Nat Med 2016;22:175–82.

[135] Zhu P, Hu S, Jin Q, et al. Ripk3 promotes ER stress-induced necroptosis in cardiac IR injury: a mechanism involving calcium overload/ XO/ROS/mPTP pathway. Redox Biol 2018;16:157–68.

[136] Xue H, Shi H, Zhang F, et al. RIP3 contributes to cardiac hypertrophy by influencing MLKL-mediated calcium influx. Oxid Med Cell Longev 2022;2022:5490553.

[137] Eguchi K, Nagai R. Islet inflammation in type 2 diabetes and physiology. J Clin Invest 2017;127:14–23.

[138] Yang B, Maddison LA, Zaborska KE, et al. RIPK3-mediated inflammation is a conserved beta cell response to ER stress. Sci Adv 2020;6.

[139] Xu H, Du X, Liu G, et al. The pseudokinase MLKL regulates hepatic insulin sensitivity independently of inflammation. Mol Metab 2019;23:14–23.

[140] Hildebrand JM, Lo B, Tomei S, et al. A family harboring an MLKL loss of function variant implicates impaired necroptosis in diabetes. Cell Death Dis 2021;12:345.

[141] Gautheron J, Vucur M, Schneider AT, et al. The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance. Nat Commun 2016;7:11869.

[142] Wang JC, Bennett M. Aging and atherosclerosis. Circ Res 2012;111:245–59.

[143] Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011;145:341–55.

[144] Karunakaran D, Geoffrion M, Wei L, et al. Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis. Sci Adv 2016;2:e1600224.

[145] Lin J, Li H, Yang M, et al. A role of RIP3-mediated macrophage necrosis in atherosclerosis development. Cell Rep 2013;3:200–10.

[146] Meng L, Jin W, Wang X. RIP3-mediated necrotic cell death accelerates systematic inflammation and mortality. Proc Natl Acad Sci U S A 2015;112:11007–12.

[147] Karunakaran D, Nguyen MA, Geoffrion M, et al. RIPK1 expression associates with inflammation in early atherosclerosis in humans and can be therapeutically silenced to reduce NF-kappaB activation and atherogenesis in mice. Circulation 2021;143:163–77.

[148] Zhang Y, Li H, Huang Y, et al. Stage-dependent impact of RIPK1 inhibition on atherogenesis: dual effects on inflammation and foam cell dynamics. Front Cardiovasc Med 2021;8.

[149] Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564–72.

[150] Jang K-H, Do Y-J, Koo T-S, et al. Protective effect of RIPK1-inhibitory compound in in vivo models for retinal degenerative disease. Exp Eye Res 2019;180:8–17.

[151] Hanus J, Anderson C, Sarraf D, et al. Retinal pigment epithelial cell necroptosis in response to sodium iodate. Cell Death Discov 2016;2.

[152] Yang M, So KF, Lam WC, et al. Novel programmed cell death as therapeutic targets in age-related macular degeneration? Int J Mol Sci 2020;21.

[153] Hanus J, Zhang H, Wang Z, et al. Induction of necrotic cell death by oxidative stress in retinal pigment epithelial cells. Cell Death Dis 2013;4:e965.

[154] Murakami Y, Matsumoto H, Roh M, et al. Programmed necrosis, not apoptosis, is a key mediator of cell loss and DAMP-mediated inflammation in dsRNA-induced retinal degeneration. Cell Death Differ 2014;21:270–7.

[155] Ibrahim SH, Hirsova P, Gores GJ. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation. Gut 2018;67:963–72.

[156] Gong Z, Tas E, Yakar S, et al. Hepatic lipid metabolism and non-alcoholic fatty liver disease in aging. Mol Cell Endocrinol 2017;455:115–30.

[157] Schwabe RF, Luedde T. Apoptosis and necroptosis in the liver: a matter of life and death. Nat Rev Gastroenterol Hepatol 2018;15:738–52.

[158] Afonso MB, Rodrigues PM, Mateus-Pinheiro M, et al. RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. Gut 2021;70:2359–72.

[159] Afonso MB, Rodrigues PM, Carvalho T, et al. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. Clin Sci (Lond) 2015;129:721–39.

[160] Roychowdhury S, McCullough RL, Sanz-Garcia C, et al. Receptor interacting protein 3 protects mice from high-fat diet-induced liver injury. Hepatology 2016;64:1518–33.

[161] Saeed WK, Jun DW, Jang K, et al. Mismatched effects of receptor interacting protein kinase-3 on hepatic steatosis and inflammation in non-alcoholic fatty liver disease. World J Gastroenterol 2018;24:5477.

[162] Majdi A, Aoudjehane L, Ratziu V, et al. Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. J Hepatol 2020;72:627–35.

[163] Kaur G, Singh NK. The role of inflammation in retinal neurodegeneration and degenerative diseases. Int J Mol Sci 2021;23.

[164] Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 1995;39:367–74.

[165] La Morgia C, Di Vito L, Carelli V, et al. Patterns of retinal ganglion cell damage in neurodegenerative disorders: parvocellular vs magnocellular degeneration in optical coherence tomography studies. Front Neurol 2017;8.

[166] Ashok A, Singh N, Chaudhary S, et al. Retinal degeneration and Alzheimer’s disease: an evolving link. Int J Mol Sci 2020;21.

[167] Huang Z, Zhou T, Sun X, et al. Necroptosis in microglia contributes to neuroinflammation and retinal degeneration through TLR4 activation. Cell Death Differ 2017;25:180–9.

[168] Heveran CM, Schurman CA, Acevedo C, et al. Chronic kidney disease and aging differentially diminish bone material and microarchitecture in C57Bl/6 mice. Bone 2019;127:91–103.

[169] Barnes JL, Glass Ii WF. Renal interstitial fibrosis: a critical evaluation of the origin of myofibroblasts. Contrib Nephrol 2011;169:73–93.

[170] Zhu Y, Cui H, Lv J, et al. Angiotensin II triggers RIPK3-MLKL-mediated necroptosis by activating the Fas/FasL signaling pathway in renal tubular cells. PLoS One 2020;15:e0228385.

[171] Fukagawa M, Noda M, Shimizu T, et al. Chronic progressive interstitial fibrosis in renal disease—are there novel pharmacological approaches? Nephrol Dial Transplant 1999;14:2793–5.

[172] Xiao X, Du C, Yan Z, et al. Inhibition of necroptosis Aatenuates kidney inflammation and interstitial fibrosis induced by unilateral ureteral obstruction. Am J Nephrol 2017;46:131–8.

[173] Nakano H, Zhu Y, Cui H, et al. RIPK3-mediated necroptosis and apoptosis contributes to renal tubular cell progressive loss and chronic kidney disease progression in rats. Plos One 2016;11.

[174] Zhu Y, Cui H, Gan H, et al. Necroptosis mediated by receptor interaction protein kinase 1 and 3 aggravates chronic kidney injury of subtotal nephrectomised rats. Biochem Biophys Res Commun 2015;461:575–81.

[175] Imamura M, Moon JS, Chung KP, et al. RIPK3 promotes kidney fibrosis via AKT-dependent ATP citrate lyase. JCI Insight 2018;3.

[176] Newton K, Dugger DL, Maltzman A, et al. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury. Cell Death Differ 2016;23:1565–76.

[177] Harapan H, Itoh N, Yufika A, et al. Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health 2020;13:667–73.

[178] da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, et al. Clinical manifestations of COVID-19 in the general population: systematic review. Wien Klin Wochenschr 2020;133:377–82.

[179] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.

[180] Wolff D, Nee S, Hickey NS, et al. Risk factors for Covid-19 severity and fatality: a structured literature review. Infection 2021;49:15–28.

[181] Jiang Y, Rubin L, Peng T, et al. Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. Int J Biol Sci 2022;18:459–72.

[182] Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020;8:e46–7.

[183] Li S, Zhang Y, Guan Z, et al. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct Target Ther 2020;5.

[184] Ruskowski K, Neb H, Talbot SR, et al. Persistently elevated plasma levels of RIPK3, MLKL, HMGB1, and RIPK1 in COVID-19 ICU patients. Am J Respir Cell Mol Biol 2022.

[185] Schweizer TA, Mairpady Shambat S, Vulin C, et al. Blunted sFasL signalling exacerbates TNF-driven neutrophil necroptosis in critically ill COVID-19 patients. Clin Transl Immunol 2021;10:e1357.

[186] Koupenova M, Corkrey HA, Vitseva O, et al. SARS-CoV-2 initiates programmed cell death in platelets. Circ Res 2021;129:631–46.

[187] Xu G, Li Y, Zhang S, et al. SARS-CoV-2 promotes RIPK1 activation to facilitate viral propagation. Cell Res 2021;31:1230–43.

RIGHTS & PERMISSIONS

The Author(s) 2022